| [1] Bradley J R, Pober J S. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene, 2001, 20(44):6482-6491.
[2] Chung J Y, Park Y C, Ye H, et al. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci, 2002, 115(Pt 4):679-688.
[3] Thomas G S, Zhang L, Blackwell K, et al. Phosphorylation of TRAF2 within its RING domain inhibits stress-induced cell death by promoting IKK and suppressing JNK activation. Cancer Res, 2009, 69(8):3665-3672.
[4] Xu L G, Li L Y, Shu H B. TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J Biol Chem, 2004, 279(17):17278-17282.
[5] Bouwmeester T, Bauch A, Ruffner H, et al. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol, 2004, 6(2):97-105.
[6] Morita Y, Kanei-Ishii C, Nomura T, et al. TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation. Mol Biol Cell, 2005, 16(11):5433-5444.
[7] Zimmer J, Lim J H, Jono H, et al. Tumor suppressor CYLD acts as a negative regulator for non-typeable haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS One, 2007, 2(10):e1032.
[8] Alvarez S E, Harikumar K B, Hait N C, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature, 2010, 465(7301):1084-1088.
[9] Kayagaki N, Phung Q, Chan S, et al. DUBA: a deubiquitinase that regulates type I interferon production. Science, 2007, 318(5856):1628-1632.
[10] Tsikitis1 M, Acosta-Alvear D, Blais A, et al. Traf7, aMyoD1 transcriptional target, regulates nuclear factor-kB activity duringmyogenesis. EMBO Mol Med, 2010, 11(12):969-976.
[11] Zotti T, Uva A, Ferravante A, et al. TRAF7 protein promotes Lys-29-linked polyubiquitination of IkappaB kinase (IKKgamma)/NF-kappaB essential modulator (NEMO) and p65/RelA protein and represses NF-kappaB activation. J Biol Chem, 2011, 286(26):22924-22933.
[12] Yoshida H, Jono H, Kai H, et al. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem, 2005, 280(49):41111-41121.
[13] Oh Y, Chung K C. UHRF2, a ubiquitin E3 ligase, acts as a small ubiquitin-like modifier E3 ligase for zinc finger protein 131. J Biol Chem, 2013, 288(13):9102-9111.
[14] Nakamura K, Johnson G L. PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway. J Biol Chem, 2003, 278(39):36989-36992.
[15] Scudiero I, Zotti T, Ferravante A, et al. Tumor necrosis factor (TNF) receptor-associated factor 7 is required for TNFalpha-induced Jun NH2-terminal kinase activation and promotes cell death by regulating polyubiquitination and lysosomal degradation of c-FLIP protein. J Biol Chem, 2012, 287(8):6053-6061.
[16] Chang L, Kamata H, Solinas G, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell, 2006, 124(3):601-613.
[17] Yang J K. FLIP as an anti-cancer therapeutic target. Yonsei Medical Journal, 2008, 49(1):19.
[18] Chen Z J. Ubiquitin Signaling in the NF-κB Pathway. Nat Cell Biol, 2005, 7(8):758-765.
[19] Clark V E, Erson-Omay E Z, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science, 2013, 339(6123):1077-1080.
[20] Reuss D E, Piro R M, Jones D T, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol, 2013, 125(3):351-358.
[21] Johnson M D, O'Connell M J, Pilcher W, et al. Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway. J Neurosurg, 2010, 112(5):934-939.
[22] Wrobel G, Roerig P, Kokocinski F, et al. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer, 2005, 114(2):249-256.
[23] Goutagny S, Yang H W, Zucman-Rossi J, et al. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res, 2010, 16(16):4155-4164.
[24] Brastianos P K, Horowitz P M, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet, 2013, 45(3):285-289.
[25] Kim E S, Shohet J M. Reactivation of p53 via MDM2 inhibition. Cell Death Dis, 2015, 6(10):e1936.
[26] Patocs A, Zhang L, Xu Y, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med, 2007, 357(25):2543-2551.
[27] Wang L, Wang L, Zhang S, et al. Downregulation of ubiquitin E3 ligase TNF receptor-associated factor 7 leads to stabilization of p53 in breast cancer. Oncol Rep, 2013, 29(1):283-287.
[28] Wu J, Liu S, Liu G, et al. Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene, 2012, 31(3):333-341.
[29] Nwabo Kamdje A H, Seke Etet P F, Vecchio L, et al. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal, 2014, 26(12):2843-2856.
[30] Napetschnig J, Wu H. Molecular basis of NF-kappaB signaling. Annu Rev Biophys, 2013, 42:443-468.
[31] Boehm D, Bacher J, Neumann H P H. Gross genomic rearrangement involving the TSC2-PKD1 contiguous deletion syndrome: characterization of the deletion event by quantitative polymerase Chain reaction deletion assay. American Journal of Kidney Diseases, 2007, 49(1):e11-e21.
[32] Libby P, Ridker P M, Hansson G K. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011, 473(7347):317-325.
[33] Wang Y, Wang F, Wu Y, et al. MicroRNA-126 attenuates palmitate-induced apoptosis by targeting TRAF7 in HUVECs. Mol Cell Biochem, 2015, 399(1-2):123-130. transduction pathway.Nat Cell Biol, 2004, 6(2):97-105. [6]Morita Y, Kanei-Ishii C, Nomura T, et al.TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation.Mol Biol Cell, 2005, 16(11):5433-5444. [7]Zimmer J, Lim J H, Jono H, et al.Tumor Suppressor CYLD Acts as a Negative Regulator for Non-Typeable Haemophilus influenza-Induced Inflammation in the Middle Ear and Lung of Mice.PLoS ONE, 2007, 2(10):e1032-. [8]Alvarez S E, Harikumar K B, Hait N C, et al.Sphingosine-1-phosphate is a missing cofactorfor the E3 ubiquitin ligase TRAF2.Nature, 2010, 465(7301):1084-1088. [9]Kayagaki N, Phung Q, Chan S, et al.DUBA: a deubiquitinase that regulates type I interferon production.Science, 2007, 318(5856):1628-1632. [10]Mary Tsikitis1 D A-A, Alexandre Blais, EricI.Traf7, aMyoD1 transcriptional target, regulates nuclear factor-kB activity duringmyogenesis. EMBO Mol Med, 2010, 11:969-976.., , :-. [11]Zotti T, Uva A, Ferravante A, et al.TRAF7 protein promotes Lys-29-linked polyubiquitination of IkappaB kinase (IKKgamma)NF-kappaB essential modulator (NEMO) and p65RelA protein and represses NF-kappaB activation.J Biol Chem, 2011, 286(26):22924-22933. [12]Yoshida H, Jono H, Kai H, et al.The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7.J Biol Chem, 2005, 280(49):41111-41121. [13]Oh Y, Chung K C.UHRF2,a ubiquitin E3 ligase,acts as a small ubiquitin-like modifier E3 ligase for zinc finger protein 131.J Biol Chem, 2013, 288(13):9102-9111. [14]Nakamura K, Johnson G L.PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway.J Biol Chem, 2003, 278(39):36989-36992. [15]Scudiero I, Zotti T, Ferravante A, et al.Tumor necrosis factor (TNF) receptor-associated factor 7 is required for TNFalpha-induced Jun NH2-terminal kinase activation and promotes cell death by regulating polyubiquitination and lysosomal degradation of c-FLIP protein.J Biol Chem, 2012, 287(8):6053-6061. [16]Chang L, Kamata H, Solinas G, et al.The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover.Cell, 2006, 124(3):601-613. [17]Yang J K.FLIP as an Anti-Cancer Therapeutic Target.Yonsei Medical Journal, 2008, 49(1):19-. [18]Chen* Z J.Ubiquitin Signaling in the NF-κB Pathway.Nat Cell Biol, 2005, 7(8):758-765. [19]Clark V E, Erson-Omay E Z, Serin A, et al.Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7,KLF4,AKT1,and SMO.Science, 2013, 339(6123):1077-1080. [20]Reuss D E, Piro R M, Jones D T, et al.Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.Acta Neuropathol, 2013, 125(3):351-358. [21]Wang L, Wang L, Zhang S, et al.Downregulation of ubiquitin E3 ligase TNF receptor-associated factor 7 leads to stabilization of p53 in breast cancer.Oncol Rep, 2013, 29(1):283-287. [22]Wu J, Liu S, Liu G, et al.Identification and functional analysis of 9p24 amplified genes in human breast cancer.Oncogene, 2012, 31(3):333-341. [23]Boehm D, Bacher J, Neumann H P H.Gross Genomic Rearrangement Involving the TSC2-PKD1 Contiguous Deletion Syndrome: Characterization of the Deletion Event by Quantitative Polymerase Chain Reaction Deletion Assay.American Journal of Kidney Diseases, 2007, 49(1):e11-e21. [24]Libby P, Ridker P M, Hansson G K.Progress and challenges in translating the biology of atherosclerosis.Nature, 2011, 473(7347):317-325. [25]Wang Y, Wang F, Wu Y, et al.MicroRNA-126 attenuates palmitate-induced apoptosis by targeting TRAF7 in HUVECs.Mol Cell Biochem, 2015, 399(1-2):123-130. |
